BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Black SW, Yamanaka A, Kilduff TS. Challenges in the development of therapeutics for narcolepsy. Prog Neurobiol 2017;152:89-113. [PMID: 26721620 DOI: 10.1016/j.pneurobio.2015.12.002] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 4.6] [Reference Citation Analysis]
Number Citing Articles
1 Deng F, Zhang Y, Zhang R, Tang Q, Guo Z, Lv Y, Wang Z, Yang Y. Compromised Dynamic Cerebral Autoregulation in Patients With Central Disorders of Hypersomnolence. Front Neurol 2021;12:634660. [PMID: 33776891 DOI: 10.3389/fneur.2021.634660] [Reference Citation Analysis]
2 Tisdale RK, Yamanaka A, Kilduff TS. Animal models of narcolepsy and the hypocretin/orexin system: Past, present, and future. Sleep 2021;44:zsaa278. [PMID: 33313880 DOI: 10.1093/sleep/zsaa278] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Wada M, Mimura M, Noda Y, Takasu S, Plitman E, Honda M, Natsubori A, Ogyu K, Tarumi R, Graff-Guerrero A, Nakajima S. Neuroimaging correlates of narcolepsy with cataplexy: A systematic review. Neurosci Res 2019;142:16-29. [PMID: 29580887 DOI: 10.1016/j.neures.2018.03.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
4 Berteotti C, Silvani A. The link between narcolepsy and autonomic cardiovascular dysfunction: a translational perspective. Clin Auton Res 2018;28:545-55. [DOI: 10.1007/s10286-017-0473-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 4.2] [Reference Citation Analysis]
5 Szabo ST, Thorpy MJ, Mayer G, Peever JH, Kilduff TS. Neurobiological and immunogenetic aspects of narcolepsy: Implications for pharmacotherapy. Sleep Med Rev 2019;43:23-36. [PMID: 30503715 DOI: 10.1016/j.smrv.2018.09.006] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 7.5] [Reference Citation Analysis]
6 Schwartz MD, Canales JJ, Zucchi R, Espinoza S, Sukhanov I, Gainetdinov RR. Trace amine-associated receptor 1: a multimodal therapeutic target for neuropsychiatric diseases. Expert Opinion on Therapeutic Targets 2018;22:513-26. [DOI: 10.1080/14728222.2018.1480723] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 6.5] [Reference Citation Analysis]
7 de Biase S, Nilo A, Gigli GL, Valente M. Investigational therapies for the treatment of narcolepsy. Expert Opin Investig Drugs 2017;26:953-63. [PMID: 28726523 DOI: 10.1080/13543784.2017.1356819] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
8 Barker EC, Flygare J, Paruthi S, Sharkey KM. Living with Narcolepsy: Current Management Strategies, Future Prospects, and Overlooked Real-Life Concerns. Nat Sci Sleep 2020;12:453-66. [PMID: 32765142 DOI: 10.2147/NSS.S162762] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
9 Mahoney CE, Mochizuki T, Scammell TE. Dual orexin receptor antagonists increase sleep and cataplexy in wild type mice. Sleep 2020;43:zsz302. [PMID: 31830270 DOI: 10.1093/sleep/zsz302] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
10 Wang YQ, Liu WY, Li L, Qu WM, Huang ZL. Neural circuitry underlying REM sleep: A review of the literature and current concepts. Prog Neurobiol 2021;204:102106. [PMID: 34144122 DOI: 10.1016/j.pneurobio.2021.102106] [Reference Citation Analysis]
11 Lam L, Anand S, Li X, Tse ML, Zhao JX, Chan EW. Efficacy and safety of naltrexone for amfetamine and methamfetamine use disorder: a systematic review of randomized controlled trials. Clin Toxicol (Phila) 2019;57:225-33. [PMID: 30451013 DOI: 10.1080/15563650.2018.1529317] [Reference Citation Analysis]
12 Fabara SP, Ortiz JF, Anas Sohail A, Hidalgo J, Altamimi A, Tama B, Patel UK. Efficacy of Pitolisant on the Treatment of Narcolepsy: A Systematic Review. Cureus 2021;13:e16095. [PMID: 34345566 DOI: 10.7759/cureus.16095] [Reference Citation Analysis]
13 Calik MW. Update on the treatment of narcolepsy: clinical efficacy of pitolisant. Nat Sci Sleep 2017;9:127-33. [PMID: 28490912 DOI: 10.2147/NSS.S103462] [Cited by in Crossref: 31] [Cited by in F6Publishing: 5] [Article Influence: 6.2] [Reference Citation Analysis]
14 Brown RE, Spratt TJ, Kaplan GB. Translational Approaches to Influence Sleep and Arousal. Brain Res Bull 2022:S0361-9230(22)00116-2. [PMID: 35550156 DOI: 10.1016/j.brainresbull.2022.05.002] [Reference Citation Analysis]
15 Vringer M, Kornum BR. Emerging therapeutic targets for narcolepsy. Expert Opin Ther Targets 2021;:1-14. [PMID: 34402358 DOI: 10.1080/14728222.2021.1969361] [Reference Citation Analysis]
16 Bhattarai J, Sumerall S. Current and Future Treatment Options for Narcolepsy: A Review. Sleep Sci 2017;10:19-27. [PMID: 28966734 DOI: 10.5935/1984-0063.20170004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
17 Anderson D. Narcolepsy: A clinical review. JAAPA 2021;34:20-5. [PMID: 34031309 DOI: 10.1097/01.JAA.0000750944.46705.36] [Reference Citation Analysis]
18 Murillo-Rodríguez E, Millán-Aldaco D, Palomero-Rivero M, Morales-Lara D, Mechoulam R, Drucker-Colín R. Cannabidiol Partially Blocks the Excessive Sleepiness in Hypocretindeficient Rats: Preliminary Data. CNS Neurol Disord Drug Targets 2019;18:705-12. [PMID: 31642794 DOI: 10.2174/1871527318666191021143300] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
19 Black SW, Schwartz MD, Chen TM, Hoener MC, Kilduff TS. Trace Amine-Associated Receptor 1 Agonists as Narcolepsy Therapeutics. Biol Psychiatry 2017;82:623-33. [PMID: 27919403 DOI: 10.1016/j.biopsych.2016.10.012] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.7] [Reference Citation Analysis]
20 Black SW, Sun JD, Santiago P, Laihsu A, Kimura N, Yamanaka A, Bersot R, Humphries PS. Partial ablation of the orexin field induces a sub-narcoleptic phenotype in a conditional mouse model of orexin neurodegeneration. Sleep 2018;41. [DOI: 10.1093/sleep/zsy116] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
21 Hopkins K, Mukherjee S, Ponce D, Mangum J, Jacobson LH, Hoyer D. Development of a LC-ESI-MRM method for the absolute quantification of orexin A in the CSF of individual mice. Medicine in Drug Discovery 2021;11:100102. [DOI: 10.1016/j.medidd.2021.100102] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Nirogi R, Benade V, Daripelli S, Subramanian R, Kamuju V, Bhyrapuneni G, Muddana NR, Mekala VR, Petlu S, Jayarajan P, Badange R, Shinde A, Jasti V. Samelisant (SUVN-G3031), a potent, selective and orally active histamine H3 receptor inverse agonist for the potential treatment of narcolepsy: pharmacological and neurochemical characterisation. Psychopharmacology (Berl) 2021;238:1495-511. [PMID: 33550481 DOI: 10.1007/s00213-021-05779-x] [Reference Citation Analysis]
23 Schwartz MD, Palmerston JB, Lee DL, Hoener MC, Kilduff TS. Deletion of Trace Amine-Associated Receptor 1 Attenuates Behavioral Responses to Caffeine. Front Pharmacol 2018;9:35. [PMID: 29456505 DOI: 10.3389/fphar.2018.00035] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
24 Thorpy MJ, Bogan RK. Update on the pharmacologic management of narcolepsy: mechanisms of action and clinical implications. Sleep Med 2020;68:97-109. [PMID: 32032921 DOI: 10.1016/j.sleep.2019.09.001] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 9.0] [Reference Citation Analysis]
25 Williams RH, Tsunematsu T, Thomas AM, Bogyo K, Yamanaka A, Kilduff TS. Transgenic Archaerhodopsin-3 Expression in Hypocretin/Orexin Neurons Engenders Cellular Dysfunction and Features of Type 2 Narcolepsy. J Neurosci 2019;39:9435-52. [PMID: 31628177 DOI: 10.1523/JNEUROSCI.0311-19.2019] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
26 Schinkelshoek MS, Smolders IM, Donjacour CE, van der Meijden WP, van Zwet EW, Fronczek R, Lammers GJ. Decreased body mass index during treatment with sodium oxybate in narcolepsy type 1. J Sleep Res 2019;28:e12684. [PMID: 29504180 DOI: 10.1111/jsr.12684] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
27 de Biase S, Pellitteri G, Gigli GL, Valente M. Evaluating pitolisant as a narcolepsy treatment option. Expert Opin Pharmacother 2021;22:155-62. [PMID: 32941089 DOI: 10.1080/14656566.2020.1817387] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
28 Liang Y, Shi W, Xiang A, Hu D, Wang L, Zhang L. The NAergic locus coeruleus-ventrolateral preoptic area neural circuit mediates rapid arousal from sleep. Curr Biol 2021:S0960-9822(21)00826-5. [PMID: 34270948 DOI: 10.1016/j.cub.2021.06.031] [Reference Citation Analysis]
29 Meskill GJ, Kallweit U, Zarycranski D, Caussé C, Finance O, Ligneau X, Davis CW. Pitolisant for the treatment of cataplexy in adults with narcolepsy. Expert Opinion on Orphan Drugs. [DOI: 10.1080/21678707.2021.2022472] [Reference Citation Analysis]